Study of the current use profile and security of oral anticoagulants in community pharmacy patients
DOI:
https://doi.org/10.60103/phc.v26.e836Keywords:
direct oral anticoagulants, vitamin K antagonists, safetyAbstract
Introduction: Direct oral anticoagulants (DOACs) have shown to be a safer, more effective, and convenient treatment option, but significantly more expensive than vitamin K antagonists (VKAs). The aim of this study was to analyze the current use profile and safety of oral anticoagulants in patients from Community Pharmacy.
Method: An observational cross-sectional study was performed on patients from 3 pharmacies in the Comunidad Autónoma de Andalucía. A questionnaire was developed, including several sociodemographic variables, data related to the volunteers’ treatment, the subjects’ knowledge about their treatment and the treatment safety.
Results: The study included both men and women in the same proportion (49 vs 51%), being more than the 50% of them older than 70. Most patients were on DOACs treatment (80%). However, when data were analyzed separately by indications, a higher percentage of patients on DOACs was detected for the treatment of non-valvular atrial fibrillation (NVAF; 92%), but the percentage was lower in patients with valve prostheses (40%). The incidence of adverse effects was lower in patients treated with DOACs. Although 89% of patients claimed to have received information about their treatment, only 13% of the subjects received this information from the pharmacist.
Conclusions: This study shows a shift in the prescription profile of OACs in favor of OACs, accounting for an improvement in the safety and convenience of anticoagulated patients and, consequently, in their quality of life.
Downloads
References
Boned-Ombuena A, Pérez-Panadés J, López-Maside A, Miralles-Espí M, Guardiola Vilarroig S, Adam Ruiz D, et al. Prevalencia de la anticoagulación oral y calidad de su seguimiento en el ámbito de la atención primaria: estudio de la Red Centinela Sanitaria de la Comunitat Valenciana. Aten Primaria [Internet]. 2017 Nov 1 [cited 2023 Dec 14];49(9):534. Available from: /pmc/articles/PMC6876010/
Hernández P, Polanco L, Santiago I, Fayos M, Valero C. Progression over time of changes in anticoagulant treatment in a tertiary hospital. Med Clin (Barc) [Internet]. 2021 Feb 12 [cited 2023 Dec 14];156(3):135–8. Available from: https://pubmed.ncbi.nlm.nih.gov/33153753/
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm [Internet]. 2019 Aug 1 [cited 2023 Dec 14];16(8):e66–93. Available from: https://pubmed.ncbi.nlm.nih.gov/30703530/
Cohen AT, Hill NR, Luo X, Masseria C, Abariga SA, Ashaye AO. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol [Internet]. 2018 Oct 15 [cited 2023 Dec 14];269:174–81. Available from: https://pubmed.ncbi.nlm.nih.gov/30037626/
Gómez-Doblas JJ, Muñiz J, Martin JJA, Rodríguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed) [Internet]. 2014 Apr [cited 2023 Dec 14];67(4):259–69. Available from: https://pubmed.ncbi.nlm.nih.gov/24774588/
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med [Internet]. 1982 Apr 29 [cited 2023 Dec 14];306(17):1018–22. Available from: https://pubmed.ncbi.nlm.nih.gov/7062992/
Muñoz Rodríguez FJ. Diagnosis of deep vein thrombosis. Rev Clin Esp [Internet]. 2020 Nov 1 [cited 2023 Dec 14];220:41–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32600570/
Gaitán Román D, Vivancos Delgado R, de Mora Martín M. Situación actual de la insuficiencia mitral: aspectos epidemiológicos y clínicos. Cardiocore. 2012 Jul 1;47(3):91–3. doi: 10.1016/j.carcor.2012.06.002
Barrios V, Cinza-Sanjurjo S, Gavín O, Egocheaga I, Burgos-Pol R, Soto J, et al. Carga y coste del mal control de la anticoagulación con antagonistas de la vitamina K en pacientes con fibrilación auricular no valvular en España. Rev Esp Cardiol [Internet]. 2021 Sep 1 [cited 2023 Dec 15];74(9):773–80. Available from: http://www.revespcardiol.org/es-carga-coste-del-mal-control-articulo-S0300893220303420
Horne M. Overview of hemostasis and thrombosis; current status of antithrombotic therapies. Thromb Res [Internet]. 2005 Jan 1 [cited 2023 Dec 15];117(1–2):15–7. Available from: http://www.thrombosisresearch.com/article/S0049384805002367/fulltext
Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, et al. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. Front Pharmacol [Internet]. 2021 May 26 [cited 2023 Dec 15];12. Available from: https://pubmed.ncbi.nlm.nih.gov/34122056/
Hindricks G, Potpara T, Kirchhof P, Kühne M, Ahlsson A, Balsam P, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J [Internet]. 2021 Feb 1 [cited 2023 Dec 19];42(5):373–498. Available from: https://pubmed.ncbi.nlm.nih.gov/32860505/
Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood [Internet]. 2018 Sep 27 [cited 2023 Dec 15];132(13):1365–71. Available from: https://pubmed.ncbi.nlm.nih.gov/30002145/
Caballero Requejo C, Urbieta Sanz E, Iniesta Navalón C, Gascón Cánovas JJ. Incorporación de los anticoagulantes de acción directa al arsenal terapéutico disponible: ¿progresa adecuadamente? Aten Primaria [Internet]. 2019 Mar 1 [cited 2023 Dec 15];51(3):184–5. Available from: https://www.elsevier.es/es-revista-atencion-primaria-27-articulo-incorporacion-anticoagulantes-accion-directa-al-S0212656718305602
Kansal AR, Zheng Y, Pokora T, Sorensen S V. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol. 2013 Jun 1;26(2):225–37. doi: 10.1007/s40256-014-0092-1
Jaramillo-Salamanca RG, Jiménez-Gómez JD, Pinilla-Roa AE. Uso de los anticoagulantes orales directos en la práctica clínica. Rev Fac Med (Bogotá) [Internet]. 2016 [cited 2023 Dec 19];64(2):295–308. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-00112016000200015
Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, Cequier Fillat Á, Roldán Rabadán I, Muñiz García J, et al. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes del «mundo real» con fibrilación auricular no valvular. Estudio FANTASIIA. Rev Esp Cardiol. 2020 Jan 1;73(1):14–20. doi: https://doi.org/10.1016/j.recesp.2019.02.003
Llisterri Caro JL, Cinza-Sanjurjo S, Polo Garcia J, Prieto Díaz MA. Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual. Medicina de Familia SEMERGEN. 2019 Sep 1;45(6):413–29. doi: 10.1016/j.semerg.2019.06.002
JW E, SJ C, M B, CB G, AP K, MJ M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med [Internet]. 2013 Dec 15 [cited 2023 Dec 19];369(13). Available from: https://pubmed.ncbi.nlm.nih.gov/23991661/
Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke [Internet]. 2017 Sep 1 [cited 2023 Dec 19];48(9):2494–503. Available from: https://pubmed.ncbi.nlm.nih.gov/28716982/
Romero MF, Gambín YG, López LF, Cabello ALR, Zaragoza JN. Conocimientos sobre el tratamiento y baja adhesión terapéutica de los pacientes anticoagulados. Salud(i)Ciencia. 2017 Mar 1;22(4):324–30. doi: http://dx.doi.org/10.21840/siic/153104
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Modesto Berraquero-Sánchez, Beatriz Somoza-Hernández, Marta Gil-Ortega
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).
